# Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer

> **NCT00917462** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 35 (actual)

## Conditions studied

- Esophageal Cancer
- Gastroesophageal Junction Cancer

## Interventions

- **DRUG:** Sorafenib, administered orally
- **PROCEDURE:** CT/MRI

## Key facts

- **NCT ID:** NCT00917462
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2018-08
- **Final completion:** 2018-08
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2019-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00917462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00917462, "Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00917462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*